



(11) **EP 2 531 177 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(51) Int Cl.:
A61K 9/16 ^(2006.01) **A61K 31/4152** ^(2006.01)
C07D 231/22 ^(2006.01) **A61P 25/00** ^(2006.01)

(48) Corrigendum issued on:
12.10.2016 Bulletin 2016/41

(86) International application number:
PCT/EP2011/051630

(45) Date of publication and mention
of the grant of the patent:
11.05.2016 Bulletin 2016/19

(87) International publication number:
WO 2011/095579 (11.08.2011 Gazette 2011/32)

(21) Application number: **11702056.0**

(22) Date of filing: **04.02.2011**

(54) **4-[2-[[5-METHYL-1-(2-NAPHTHALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE
HYDROCHLORIDE POLYMORPHS AND SOLVATES**

4-[2-[[5-METHYL-1-(2-NAPHTHALINYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLIN
HYDROCHLORID POLYMORPHE UND SOLVATE

POLYMORPHES D'UN SEL DE CHLORHYDRATE DE

4-[2-[[5-METHYL-1-(2-NAPHTHALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE ET DES
SOLVATES

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME

- **BENET BUCHHOLZ, Jordi**
E-43893 Altafulla - Tarragona (ES)
- **PUIG FERNANDEZ, Laura**
E-50019 Zaragoza (ES)
- **PELLEJÀ PUXEU, Laia**
E-43007 Tarragona (ES)

(30) Priority: **09.08.2010 EP 10382226**
04.02.2010 EP 10382025

(74) Representative: **ABG Patentes, S.L.**
Avenida de Burgos, 16D
Edificio Euromor
28036 Madrid (ES)

(43) Date of publication of application:
12.12.2012 Bulletin 2012/50

(73) Proprietor: **Laboratorios del Dr. Esteve, S.A.**
08041 Barcelona (ES)

(56) References cited:
EP-A1- 2 113 501 WO-A1-2006/021462

(72) Inventors:

- **BERENGUER MAIMÓ, Ramón**
E-08001 Barcelona (ES)
- **MEDRANO RUPÉREZ, Jorge**
E-08921 Santa Colònia de Gramenet
Barcelona (ES)

EP 2 531 177 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- LEE S ET AL: "Handbook of Pharmaceutical Salts: Properties, Selection , and Use, Chapter 8 (Large-Scale Aspects of Salt Formation: Processing of Intermediates and Final Products, Chapter 12 (Monographs on Acids and Bases)", 1 January 2002 (2002-01-01), HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, ZÜRICH : VERL. HELVETICA CHIMICA ACTA ; WEINHEIM [U.A.] : WILEY-VCH, DE, PAGE(S) 191 - 192,211, XP002548973, ISBN: 978-3-906390-26-0 page 192 page 211 - page 213
- BERGE S METAL: "PHARMACEUTICAL SALTS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 66, no. 1, 1 January 1977 (1977-01-01), pages 1-19, XP002552191, ISSN: 0022-3549, DOI: DOI:10.1002/JPS.2600660104

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification